Home/Pipeline/CD123 x γδ T-cell Engager

CD123 x γδ T-cell Engager

Acute Myeloid Leukemia (AML)

Pre-clinicalActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Pre-clinical

Status

Active

Company

92Bio

About 92Bio

92Bio is a private, preclinical-stage biotech focused on developing best-in-class multispecific T-cell engagers for oncology. Its lead program, NTB-928 (FRα x CD3), is slated for clinical entry in H1 2026, with a γδ T-cell engager for AML following in 2027. The company is backed by experienced venture capital investors and is headquartered in Hayward, California, with a culture emphasizing innovation, collaboration, and calculated risk-taking.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active